Saber Soltani

Dr. Saber Soltani

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Saber SoltaniSaber Soltani
Saber Soltani
AZArmin Zakeri
Armin Zakeri
MZMilad Zandi
Milad Zandi
MKMina Mobini Kesheh
Mina Mobini Kesheh
ATAlireza Tabibzadeh
Alireza Tabibzadeh
AFAbbas Farahani
Abbas Farahani
Recently, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the etiologic agent of coronavirus disease 2019 (COVID‐19), has led to a worldwide pandemic with millions of infected patients. Alteration in humans’ microbiota was also reported in COVID‐19 patients. The alteration in human microbiota may contribute to bacterial or viral infections and affect the immune system. Moreover, human’s microbiota can be altered due to SARS‐CoV‐2 infection, and these microbiota changes can indicate the progression of COVID‐19. While current studies focus on the gut microbiota, it seems necessary to pay attention to the lung microbiota in COVID‐19. This study is aimed at reviewing respiratory microbiota dysbiosis among COVID‐19 patients to encourage further studies on the field for assessment of SARS‐CoV‐2 and respiratory microbiota interaction.

1 December 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
RPReza Pakzad
Reza Pakzad
PMPooneh Malekifar
Pooneh Malekifar
ZSZainab Shateri
Zainab Shateri
MZMilad Zandi
Milad Zandi
SRSara Akhavan Rezayat
Sara Akhavan Rezayat
PHParastoo Hosseini
Parastoo Hosseini
Background: To provide information about pathogens’ coinfection prevalence with SARS‐CoV‐2 could be a real help to save patients’ lives. This study aims to evaluate the pathogens’ coinfection prevalence among COVID‐19 patients.Method: In order to find all of the relevant articles, we used systematic search approach. Research‐based databases including PubMed, Web of Science, Embase, and Scopus, without language restrictions, were searched to identify the relevant bacterial, fungal, and viral coinfections among COVID‐19 cases from December 1, 2019, to August 23, 2021. In order to dig deeper, other scientific repositories such as Medrxiv were probed.Results: A total of 13,023 studies were found through systematic search. After thorough analysis, only 64 studies with 61,547 patients were included in the study. The most common causative agents of coinfection among COVID‐19 patients were bacteria (pooled prevalence: 20.97%; 95% CI: 15.95–26.46; I2: 99.9%) and less frequent were virus coinfections (pooled prevalence: 12.58%; 95% CI: 7.31–18.96; I2: 98.7%). The pooled prevalence of fungal coinfections was also 12.60% (95% CI: 7.84–17.36; I2: 98.3%). Meta‐regression analysis showed that the age sample size and WHO geographic region did not influenced heterogeneity.Conclusion: We identified a high prevalence of pathogenic microorganism coinfection among COVID‐19 patients. Because of this rate of coinfection empirical use of antibacterial, antifungal, and antiviral treatment are advisable specifically at the early stage of COVID‐19 infection. We also suggest running simultaneously diagnostic tests to identify other microbiological agents’ coinfection with SARS‐CoV‐2.

24 September 2020 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Open access
PDF file
MFMona Fani
Mona Fani
MZMilad Zandi
Milad Zandi
Saber SoltaniSaber Soltani
Saber Soltani
SASamaneh Abbasi
Samaneh Abbasi
According to the evidence, the coronavirus disease 19 (COVID‐19) is caused by a zoonotic pathogen named respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This virus can spread through personal contact, respiratory droplets, and also through airborne transmission. A rapid, low‐cost, and effective biosensor platform is essential to diagnose patients with COVID‐19 infection, predominantly the asymptomatic individuals, and prevent the spread of the SARS‐CoV‐2 via transmission routes. The objective of this review is to provide a comparative view among current diagnostic methods, focusing on recently suggested biosensors for the detection of SARS‐CoV2 in clinical samples. A capable SARS‐CoV‐2 biosensor can be designed by the holistic insights of various biosensor studies.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PMPooneh Malekifar
Pooneh Malekifar
RPReza Pakzad
Reza Pakzad
RSRamin Shahbahrami
Ramin Shahbahrami
MZMilad Zandi
Milad Zandi
AJAli Jafarpour
Ali Jafarpour
Saber SoltaniSaber Soltani
Saber Soltani
Background. Coinfections have a potential role in increased morbidity and mortality rates during pandemics. Our investigation is aimed at evaluating the viral coinfection prevalence in COVID‐19 patients. Methods. We systematically searched scientific databases, including Medline, Scopus, WOS, and Embase, from December 1, 2019, to December 30, 2020. Preprint servers such as medRxiv were also scanned to find other related preprint papers. All types of studies evaluating the viral coinfection prevalence in COVID‐19 patients were considered. We applied the random effects model to pool all of the related studies. Results. Thirty‐three studies including 10484 patients were identified. The viral coinfection estimated pooled prevalence was 12.58%; 95% CI: 7.31 to 18.96). Blood viruses (pooled prevalence: 12.48%; 95% CI: 8.57 to 16.93) had the most frequent viral coinfection, and respiratory viruses (pooled prevalence: 4.32%; 95% CI: 2.78 to 6.15) had less frequent viral coinfection. The herpesvirus pooled prevalence was 11.71% (95% CI: 3.02 to 24.80). Also, the maximum and minimum of viral coinfection pooled prevalence were in AMRO and EMRO with 15.63% (95% CI: 3.78 to 33.31) and 7.05% (95% CI: 3.84 to 11.07), respectively. Conclusion. The lowest rate of coinfection belonged to respiratory viruses. Blood‐borne viruses had the highest coinfection rate. Our results provide important data about the prevalence of blood‐borne viruses among COVID‐19 patients which can be critical when it comes to their treatment procedure.

1 September 2021 in New Microbes and New Infections
Verified
Journal Article
Open access
Saber SoltaniSaber Soltani
Saber Soltani
SFS. Faramarzi
S. Faramarzi
MZM. Zandi
M. Zandi
RSR. Shahbahrami
R. Shahbahrami
AJA. Jafarpour
A. Jafarpour
RPR. Pakzad
R. Pakzad
The pandemic of severe acute respiratory syndrome coronavirus 2 raised the attention towards bacterial coinfection and its role in coronavirus disease 2019 (COVID-19) disease. This study aims to systematically review and identify the pooled prevalence of bacterial coinfection in the related articles. A comprehensive search was conducted in international databases, including MEDLINE, Scopus, Web of Science, and Embase, to identify the articles on the prevalence of bacterial coinfections in COIVD-19 patients from 1 December 2019 until 30 December 2020. All observational epidemiological studies that evaluated the prevalence of bacterial coinfections in patients with COVID-19 were included without any restriction. Forty-two studies including a total sample size of 54,695 were included in the analysis. The pooled estimate for the prevalence of bacterial coinfections was 20.97% (95% CI: 15.95–26.46), and the pooled prevalence of bacterial coinfections was 5.20% (95% CI: 2.39–8.91) for respiratory subtype and 4.79% (95% CI: 0.11–14.61) for the gastrointestinal subtype. The pooled prevalence for Eastern Mediterranean Regional Office and South-East Asia Regional Office was 100% (95% CI: 82.35–100.00) and 2.61% (95% CI: 1.74–3.62). This rate of coinfection poses a great danger towards patients, especially those in critical condition. Although there are multiple complications and adverse effects related to extensive use of antibiotics to treat patients with COVID-19, it seems there is no other option except applying them, and it needs to be done carefully.

1 January 2018 in Advances in Human Biology
Verified
Journal Article
Open access
PDF file
PMParviz Mohajeri
Parviz Mohajeri
Saber SoltaniSaber Soltani
Saber Soltani
AFAbbas Farahani
Abbas Farahani
MDMahsa Dastranj
Mahsa Dastranj
NMNavid Momenifar
Navid Momenifar
AEAmir Darb Emamie
Amir Darb Emamie
Infectious diseases are the biggest cause of mortality and morbidity in humans, especially in poor and developing countries. For many years, no new vaccine has been developed, which indicates the limitations of the development of common vaccines, including destruction and inactivation of the vaccine, weakened vaccines toxoids known as first-generation vaccines. Types of vaccines including: (1) First-generation vaccines, (2) second-generation vaccines or recombinant vaccines, (3) third-generation vaccines (gene vaccine). The study on DNA vaccines first began in the 1990s, when the plasmid DNA is injected into the skin or muscle was reported to induce antibody responses to antigens. Since DNA vaccines are easily designed and manufactured, they are easier to preserve them, and they are inexpensive, as one of the most desirable types of vaccine. However, more clinical trials are needed to prove the immune responses that immune to DNA vaccine in humans. Information on the vaccination method, adjuvant and the genetic structure of the vaccine is still not complete.